Virological characteristics of SARS-CoV-2 BA2 variant: more pathogenic than BA1

Re:Virological characteristics of SARS-CoV-2 BA2 variant: mo... by xiphias2 on Sunday February 20, 2022 @10:25PM (#30411641)

Does it really matter that it's resistant to BA.1 induced humoral immunity?

From the BA.1 variant we learned that cell mediated immunity is more important to end the pandemic.

The media got very loud that the 4th vaccine doesn't help to stop people from getting sick, but it required a month more data to see that it is worth to be injected to decrease the probability of serious illness / death.

[ Parent | on HN ]

Re:Virological characteristics of SARS-CoV-2 BA2 variant: mo... by data_acquired on Sunday February 20, 2022 @10:46PM (#30411762)

Yeah, its not clear if preventing symptomatic infection is as crucial an end-point in contrast to preventing hospitalization, the latter of which is indeed mediated by T-cell immunity rather than antibody titers. The following detail is worth noting though ---

"Vaccine sera were collected from sixteen vaccinees four weeks after the second vaccination with mRNA-1273 (Moderna)"

So it seems like they haven't tested against sera from people who got three doses? Response to BA.1 was better with three doses than two, but I think if the data from Israel was to go by, the impact of the third dose on antibody titers also waned over time (although T-cell mediated immunity stayed the same in terms of % hospitalized).

[ Parent | on HN ]

Re:Virological characteristics of SARS-CoV-2 BA2 variant: mo... by rastignack on Monday February 21, 2022 @12:05AM (#30412154)

> Response to BA.1 was better with three doses than two

Not under 60, though.

[ Parent | on HN ]

Re:Virological characteristics of SARS-CoV-2 BA2 variant: mo... by EdwardDiego on Monday February 21, 2022 @01:03AM (#30412424)

Source?

[ Parent | on HN ]